Novo Nordisk A/S (NYSE:NVO) Stock Position Raised by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,263 shares of the company’s stock after buying an additional 607 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Novo Nordisk A/S were worth $1,062,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. CNB Bank bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $26,000. Pacific Center for Financial Services lifted its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. Valued Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $28,000. Bell Investment Advisors Inc raised its holdings in shares of Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the period. Finally, Tyler Stone Wealth Management raised its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. UBS Group started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Finally, BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Stock Up 0.0 %

Shares of NVO stock traded up $0.04 during trading hours on Wednesday, hitting $127.33. 232,606 shares of the company’s stock traded hands, compared to its average volume of 4,789,627. The stock’s fifty day simple moving average is $127.33 and its two-hundred day simple moving average is $113.50. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The stock has a market cap of $571.40 billion, a price-to-earnings ratio of 43.89, a PEG ratio of 1.93 and a beta of 0.43. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.